James Reid, Venu Pullabhatla, Laura Parkes, John Shovelton, Ezam Uddin, Lyudmila Georgieva, Aysel Heckel, Jolyon Holdstock, Graham Speight
Next-Generation Sequencing (NGS) has enabled large-scale identification of variants with increased reliability and accuracy. This is crucial for detecting low-frequency variants for cancer research.
At OGT, we have developed Interpret, as a partner software tool to our CytoSure® and SureSeq™ NGS panels, to facilitate data analysis in an easy, user-friendly way. Interpret has been benchmarked with known and validated variants from control reference standards achieving high concordance.
Once you have registered with us for free you will be able to read all our supportive literature, video tutorials and webinars.